Marrone Bio Innovations To Open Bangor, Michigan, Manufacturing Facility
08/06/2012
MBI officials said its new facility will provide the necessary capacity to advance its growing pipeline of natural pest management products, or biopesticides, for the agriculture and water treatment markets.
"This marks a significant milestone for MBI," said CEO Pam Marrone. "Having our own manufacturing facility will be a tremendous asset to us, both in terms of cost effectiveness and quality assurance for our existing products and as we seek to rapidly advance our pipeline of new products from development to commercialization."
The site is former a biodiesel production facility, which was most recently used for production of glycerin. MBI will begin retrofitting and repurposing the site for fermentation this month, and intends to initiate manufacturing in early 2013. In addition to the manufacturing plant, the site includes offices and a laboratory. The facility will initially employ up to 30 people, but MBI intends to increase employment to 50 workers over the next few years.
MBI anticipates manufacturing Grandevo, a broad-spectrum bioinsecticide for controlling insects and mites, as well as Zequanox, the industry's first naturally derived product for controlling invasive zebra and quagga mussels at the new facility.
In addition to Grandevo and Zequanox, MBI has several early stage products that if developed will ultimately be manufactured in Bangor. Those include an EPA-approved bioherbicide and an additional insecticide, currently undergoing EPA review. Additionally, the company has several nematicide, herbicide, fungicide, algaecide and plant health product candidates under development that could be produced at the site.
Financial details about the firm's investment were not disclosed; however, MBI noted its executive team has extensive experience acquiring, developing and operating fermentation facilities.
While information on incentives offered the firm was not immediately available, Don Glidewell, MBI chief financial officer said. "With this acquisition we lay the cornerstone of our manufacturing strategy. We anticipate that operating our own site will provide MBI additional capacity and flexibility to efficiently manufacture new products. At the same time, MBI will maintain certain strategic contract manufacturing partnerships, which we expect will mitigate the risk of single source of production."
Project Announcements
Little Leaf Farms Plans Coffee County, Tennessee, Production Operations
07/02/2025
White Rock Truss & Components Expands Lee County, Virginia, Operations
07/02/2025
Fox Tank Company Plans Coshocton, Ohio, Operations
07/02/2025
Ascentek Expands Shreveport, Louisiana, Operations
07/02/2025
ProBio Establishes Hopewell, New Jersey, Gene Therapy Operations
07/02/2025
22nd Century Technologies Expands Fairfax County, Virginia, Headquarters Operations
07/02/2025
Most Read
-
20th Annual Area Development Gold and Silver Shovel Awards
Q2 2025
-
First Person: Joe Capes, CEO, LiquidStack
Q2 2025
-
The Legal Limits of DEI in Incentives Agreements, Hiring, and Contracting
Q2 2025
-
From Silicon to Server: Mapping the Data Center Supply Chain
Q2 2025
-
Rethinking Life Sciences Site Selection in a Resilient and Dynamic Market
Q2 2025
-
39th Annual Corporate & 21st Annual Consultants Surveys: What Business Leaders and Consultants Are Saying About Site Selection
Q1 2025
-
First Person: David Robey, Co-CEO of QTS Data Centers
Q2 2025